Study IVF116828:A Multi-Cohort Phase I Study to Investigate the Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban (GSK557296) in Healthy Female Volunteers During Control and Challenge States With and Without Oxytocin

Trial Profile

Study IVF116828:A Multi-Cohort Phase I Study to Investigate the Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban (GSK557296) in Healthy Female Volunteers During Control and Challenge States With and Without Oxytocin

Discontinued
Phase of Trial: Phase I

Latest Information Update: 11 May 2017

At a glance

  • Drugs Epelsiban (Primary) ; Ethinylestradiol/norgestimate; Oxytocin; Oxytocin
  • Indications Female infertility
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 13 Jun 2016 Status changed from recruiting to discontinued.
    • 21 Apr 2016 Planned End Date changed from 1 Aug 2015 to 1 May 2016.
    • 21 Apr 2016 Planned primary completion date changed from 1 Aug 2015 to 1 May 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top